tradingview.comOCT 231 min read$TEM

Tempus AI Signs $192.5 Million Data Agreements with BMS and Pathos

Tempus AI secured $192.5M in data agreements with BMS and Pathos AI. BMS will pay $137.5M for oncology data and software by 2031. Pathos may pay up to $55M for neurology data and tools, with payments tied to data delivery. Tempus restricted certain records from third-party licensing. According to the company's SEC filing.

Original reporting

tradingview.com

Published Oct 23, 2026, 1:03 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Oct 23, 2026, 1:07 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Tempus AI Signs $192.5 Million Data Agreements with BMS and Pathos — source image — Source · tradingview.com

Decision brief

The 30-second read

$TEMBullishHigh

Why it matters

The deals provide immediate cash and long‑term recurring revenue, likely improving Tempus' financial outlook and stock valuation.

Market read

First‑report of a large, strategic data licensing deal that could materially affect Tempus AI's revenue and market perception.

What to watch

Potential regulatory scrutiny of data sharing agreements and reliance on a few large pharma customers.

Relevance 7/10Novelty 9/10Timing: today

Background

Tempus AI filed an 8‑K announcing multi‑year data licensing agreements with Bristol‑Myers Squibb and Pathos AI, totaling up to $192.5 million.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$TEMBullishHigh confidence

Context

Tempus AI disclosed $192.5 million data agreements with Bristol‑Myers Squibb and Pathos AI, providing up‑front payments and future revenue streams.

Expected impact

likely upward pressure as the market prices in the new multi‑hundred‑million revenue stream

Evidence & confidence

First‑report 8‑K filing, sizable cash component, and strategic partnership with a major pharma partner.

Market effects

Sector

May boost sentiment for health‑data and AI‑driven biotech service providers.

Regional

U.S. biotech sector could see modest gains.

Global

Highlights growing pharma demand for AI‑enabled data platforms.

Counterpoint

What could challenge this read

If integration challenges arise, the contracts could strain Tempus' resources and delay revenue.

Key entities

company
Tempus AI, Inc.
U.S. listed provider of AI‑driven clinical data platforms.
company
Bristol‑Myers Squibb
Major pharmaceutical company partnering for oncology data.
company
Pathos AI
AI firm collaborating on neurology data.

Read at source ← All news

OCT 23

$BMYLow

Pathos AI teams up with Bristol Myers and Tempus AI to advance drug development

Pathos AI partnered with Bristol Myers Squibb and Tempus AI to develop AI tools for drug development in Alzheimer's and other neurological disorders. The company raised $237 million in a Series E funding round led by Bristol Myers, valuing it at $3 billion. Pathos will license data from Tempus for $55 million over five years and use its AI platform, Pathos Foundry, to study the dataset and design clinical trials. Bristol Myers gains non-exclusive access to Pathos Foundry.

finance.yahoo.com2 min

OCT 23

$TEMHighAI 9/10

Tempus AI, Inc. announced that it had entered into a series of agreements with Bristol-Myers Squibb Company and Pathos AI, Inc. to expand the use of Tempus’s…

Tempus AI, Inc. (TEM) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On October 23, 2026, Tempus AI, Inc. (“Tempus”) announced that it had entered into a series of agreements with Bristol-Myers Squibb Company (“BMS”) and Pathos AI, Inc. (“Pathos”) to expand the use of Tempus’s de-identified multimodal real-world data, data

SEC EDGAR 8-K2 min

OCT 19

$TEMMedAI 8/10

Tempus AI, Inc. (TEM) Reports >80% Sensitivity In AI NSCLC Pre-Screen

Tempus AI reported >80% sensitivity in its AI NSCLC pre-screening panel across 12 biomarkers, with some >90%, from a 60,459-case analysis presented at ESMO 2026. The tool is in development to prioritize confirmatory testing.

tradingview.com2 min

OCT 7

$TEMMed

Tempus AI Doubles Down On Moderna and Merck Cancer Vaccine Infrastructure - Tempus AI (NASDAQ:TEM)

Tempus Inc. (TEM) expanded its collaboration with Moderna (MRNA) and Merck (MRK) to support the development of a cancer vaccine. Tempus will manage sample collection and provide NGS services. The company also partnered with Bristol Myers Squibb (BMY) to improve clinical trial design. Additionally, Tempus acquired Personalis (PSNL) for $1.5 billion to enhance cancer monitoring. TEM shares were down 1.94% to $70.58 at the time of publication.

benzinga.com3 min

OCT 6

$TEMMed

Tempus AI Stock After FDA Clearance for AI Heart Valve Detection

Tempus AI received FDA clearance for its AI tool, ECG-MR, which detects potential heart valve issues in at-risk patients. This expands the company's AI software offerings into cardiovascular diagnostics. Analysts project revenues of $2.6B and earnings of $18.7M by 2029, assuming 22% yearly revenue growth. The company aims to integrate its data and software tools across various medical fields, including oncology, genetics, and now cardiology.

simplywall.st3 min

OCT 2

$EWHighAI 8/10

Weekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report Data

Edwards Lifesciences (EW) received FDA approval for a pediatric heart valve. Ceribell (CBLL) and SI-BONE (SIBN) cleared new software and spinal fusion systems. Teva (TEVA) added a biosimilar to its portfolio. AbbVie (ABBV) and Mirum (MIRM) gained FDA approvals for Parkinson's and rare disease treatments. Merck (MRK) withdrew a lung cancer drug filing. Sanofi (SNY) and Regeneron (REGN) expanded their immunology alliance.

rttnews.com3 min